| Outcome Measures: |
Primary: Changes from baseline following 8-week treatment with linagliptin vs glimepiride on fasting and postprandial renal hemodynamics, measured as GFR / ERPF (determined by inulin/para-aminohippuric-acid clearance), 8 weeks | Secondary: Renal tubular function, 8 weeks|Renal damage, measured by urine biomarkers, 8 weeks|Blood Pressure and Heart Rate, 8 weeks | Other: Body anthropometrics: body weight, height, body mass index, waist circumference, 8 weeks|Body fat content, 8 weeks|Systemic hemodynamic variables (blood pressure, heart rate, stroke volume, cardiac output/-index, total systemic vascular resistance), Derived from non-invasive beat-to-beat finger blood pressure measurements, 8 weeks|Cardiac autonomic nervous system function, 8 weeks|Microvascular function, 8 weeks|Arterial stiffness, 8 weeks|Glycemic variables, Glycated hemoglobin (HbA1c) and fasting glucose, 8 weeks|Lipid spectrum, 8 weeks|DPP4- and ACE activity, 8 weeks
|
